Yang Bing-Jie, Zhou Hai-Feng, Liu Yu, Yang Wei, Li Jia, Zhou Wei-Zhong
Department of Ultrasound, Zhongda Hospital, Southeast University, Nanjing, China.
Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Transl Gastroenterol Hepatol. 2024 Nov 11;10:14. doi: 10.21037/tgh-24-53. eCollection 2025.
Ultrasound (US)-targeted microbubble (MB) destruction (UTMD) involves the application of low-intensity US to MBs. This review is to illustrate the current progress and futural prospects of UTMD for liver diseases.
A review of the most recent literature concerning the use of UTMD for liver diseases is presented from January 2000 to December 2023. A comprehensive search was conducted by two independent reviewers. In this review, we provide an overview of various preclinical applications of UTMD in the delivery of drugs and genes to target liver diseases, including liver cancer, liver fibrosis, and hepatic gene deficiency disorders, which have established the safety and effectiveness.
A total of 9 studies and 14 studies were identified about the preclinical applications for drug-loaded and gene-loaded UTMD for liver diseases, respectively. UTMD allows specific substances to bypass physiological barriers and reach target tissues or organs. It has been demonstrated to enhance hepatic disease drug delivery. UTMD still requires improvement in many areas, including sonographic parameters, drug-loading capacity, and range of treatable diseases.
UTMD was shown in preclinical studies to enhance the therapeutic efficacy of drug delivery and gene therapy for liver cancer, liver fibrosis and hepatic gene defect diseases. Further clinical trials are emergent to evaluate the safety, effectiveness and long-term efficacy of UTMD in treating human liver diseases.
超声（US）靶向微泡（MB）破坏（UTMD）是指将低强度超声应用于微泡。本综述旨在阐述UTMD在肝脏疾病治疗方面的当前进展和未来前景。
对2000年1月至2023年12月期间有关UTMD用于肝脏疾病治疗的最新文献进行综述。由两名独立评审员进行全面检索。在本综述中，我们概述了UTMD在针对肝脏疾病（包括肝癌、肝纤维化和肝脏基因缺陷疾病）的药物和基因递送方面的各种临床前应用，这些应用已证实了其安全性和有效性。
分别确定了9项和14项关于载药和载基因UTMD用于肝脏疾病临床前应用的研究。UTMD可使特定物质绕过生理屏障并到达靶组织或器官。已证明它能增强肝脏疾病的药物递送。UTMD在许多方面仍需改进，包括超声参数、载药能力和可治疗疾病范围。
临床前研究表明，UTMD可提高肝癌、肝纤维化和肝脏基因缺陷疾病的药物递送和基因治疗的疗效。迫切需要进一步开展临床试验，以评估UTMD治疗人类肝脏疾病的安全性、有效性和长期疗效。
